Valuation: Kura Oncology, Inc.

Market Cap 1.02B 889M 820M 757M 1.44B 96.94B 1.46B 9.8B 3.85B 47.76B 3.82B 3.73B 164B P/E 2026 *
-3.24x
P/E 2027 * -4.33x
Enterprise Value 856M 748M 690M 638M 1.21B 81.61B 1.23B 8.25B 3.24B 40.2B 3.21B 3.14B 138B EV / Sales 2026 *
9x
EV / Sales 2027 * 6.5x
Free-Float
98.57%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Kura Oncology, Inc.

1 day-5.22%
1 week+3.15%
Current month+4.38%
1 month+29.23%
3 months+32.06%
6 months+21.68%
Current year+10.20%
1 week 10.71
Extreme 10.71
12.22
1 month 9.04
Extreme 9.04
12.22
Current year 7.36
Extreme 7.3575
12.22
1 year 5.45
Extreme 5.45
12.49
3 years 5.41
Extreme 5.41
24.17
5 years 5.41
Extreme 5.41
24.17
10 years 3.32
Extreme 3.3188
43
Manager TitleAgeSince
Chief Executive Officer 57 21/08/2014
Chief Tech/Sci/R&D Officer 64 01/01/2025
Chief Tech/Sci/R&D Officer 48 01/01/2025
Director TitleAgeSince
Chairman 57 28/02/2015
Director/Board Member 67 26/04/2015
Director/Board Member 57 13/10/2015
Date Insider Type Main position Quantity % Market Cap.
06-17Sell

Chief Technology Officer

-84,929 0.0957%
06-03Free

Director

35,000 0.0394%
06-03Free

Director

35,000 0.0394%
Change 5-day change 1-year change 3-year change Capi.($)
-5.22%+3.15%+82.32%+15.66% 1.02B
+1.84%-0.66%+59.82%+92.96% 54.88B
-4.14%-8.06%+58.96%+118.67% 54.63B
-2.24%+3.59%+17.75%+477.47% 25.06B
-1.60%-6.21%-18.96%-15.21% 23.14B
+2.43%+1.06%+42.44%-1.27% 19.87B
-3.19%0.00%+35.60%-26.98% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
+8.74%+3.51%+51.91%+726.40% 15.75B
-1.05%+1.16%+25.95%+194.27% 14.2B
Average -1.13%+0.63%+55.09%+193.91% 24.26B
Weighted average by Cap. -0.91%-1.41%+51.39%+176.46%

Financials

2026 *2027 *
Net sales 95.04M 83.13M 76.68M 70.82M 134M 9.06B 137M 916M 360M 4.47B 357M 349M 15.35B 215M 188M 173M 160M 303M 20.46B 308M 2.07B 812M 10.08B 806M 788M 34.66B
Net income -314M -274M -253M -234M -444M -29.92B -451M -3.02B -1.19B -14.74B -1.18B -1.15B -50.67B -248M -217M -200M -185M -351M -23.65B -357M -2.39B -939M -11.65B -931M -911M -40.06B
Net Debt -161M -141M -130M -120M -227M -15.34B -231M -1.55B -609M -7.56B -604M -591M -25.97B 379M 332M 306M 282M 536M 36.15B 545M 3.65B 1.43B 17.81B 1.42B 1.39B 61.22B
Logo Kura Oncology, Inc.
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies.
Employees
260
Date Price Change Volume
10/07/26 US$11.45 -5.22% 1,338,778
09/07/26 US$12.08 -0.33% 1,414,362
08/07/26 US$12.12 +1.08% 1,918,782
07/07/26 US$11.99 +8.61% 3,812,066
06/07/26 US$11.04 -0.54% 1,351,233
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
11.45USD
Average target price
31.17USD
Spread / Average Target
+172.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KURA Stock